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Background: Epilepsy is a complex chronic disorder which affects health-related quality of life (HRQOL), especially
in women.
Pharmaceutical care (PC) allows direct intervention between the pharmacist, the patient and the other healthcare
team members to optimise treatments in order to reduce negative outcomes related to medication and contribute
to improving HRQOL.
The aim of the study was to establish the impact of the application of a pharmaceutical care programme on the
HRQOL of women with epilepsy.
Methods: This study is a pragmatic randomised controlled trial involving women with epilepsy (WWE) over
18 years of age.
The intervention group (IG) received a pharmaceutical care programme consisting of medication review follow-up
according to Dáder’s method, health education and therapeutic drug monitoring of anticonvulsants.
The impact was assessed by changes in seizure frequency, in the self-administered questionnaires (the QOLIE-31,
Liverpool AEP, CES-D, Haynes-Sackett test and Moriski-Green test) and between the first interview and the one at
the end of six months of follow-up.
A Student’s t-test was performed to compare the final QOLIE-31 score between groups and a paired Student’s t-test
was used to determine the change in each group between the start and the end of follow-up.
Results: One hundred eighty-two WWE entered the study and 144 (79.1%) completed it. The t-test for comparing
the final QOLIE-31 scores between groups yielded a t = −2.166 and confidence interval (CI) (95%): −10.125; −0.4625,
p-value =0.0319. The change (Δ) in the QOLIE-31 score for the IG was 12.45 points (p-value <0.001) and for the
control group it was 2.61 (p-value =0.072). With 10.7 as the minimally important change we found a relative risk of
2.17 (CI: 1.37; 3.43) and a number needed to treat (NNT) of 3.5.
Conclusions: The study demonstrated that the application of a pharmaceutical care programme significantly
improves HRQOL in WWE. The NNT we found allows a recommendation to implement the PC programme for the
additional benefit that would be obtained in patients’ HRQOL.
Trial registration: Current Controlled Trials ISRCTN46864306 IPHIWWE study.
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Antecedentes: La epilepsia es un desorden crónico complejo que afecta la calidad de vida relacionada con la
salud (CVRS), especialmente en las mujeres.
La atención farmacéutica (AF) permite la interacción directa del farmacéutico con el paciente y con los demás
integrantes del equipo de salud para optimizar los tratamientos con el fin de disminuir los resultados negativos
asociados con la medicación y contribuir a mejorar la CVRS.
El objetivo del estudio fue establecer el impacto de la aplicación de un programa de AF en la CVRS de mujeres con
epilepsia (MCE).
Métodos: Ensayo clínico controlado aleatorizado pragmático en MCE mayores de 18 años.
Al grupo intervención se le aplicó un programa de AF consistente en seguimiento farmacoterapéutico según el
método Dáder, educación para la salud y monitoreo de anticonvulsivantes.
El impacto se evaluó con el cambio en la frecuencia de crisis y de los cuestionarios auto-administrados (QOLIE-31,
Liverpool AEP, CES-D, test de Haynes-Sackett, y test de Moriski-Green) entre la primera entrevista y al finalizar los seis
meses de seguimiento.
Se realizó una t de student para comparar el puntaje final entre los grupos y una t de student pareada para
comparar el cambio en el QOLIE-31 entre el inicio y el final en cada grupo.
Resultados: Se incluyeron 182 pacientes y finalizaron 144 (79,1%). La prueba t para QOLIE-31 final entre grupos
arrojó un t = −2,166 (IC [95%]: −10,125 -0,4625; p = 0,0319). Para el GI el cambio (Δ) en el QOLIE-31 fue de 12,45
puntos (p <0,001) y para el GC de 2,61 (p =0,072). Tomando 10,7 como cambio mínimo importante se encontró un
Riesgo Relativo de 2,17 (IC: 1,37-3,43) y un Número Necesario a Tratar (NNT) de 3,5.
Conclusiones: El estudio demostró que la aplicación del programa de AF mejora significativamente la CVRS en
MCE. El NNT encontrado nos permite recomendar la implementación del programa de AF por el beneficio adicional
que se obtendría en la CVRS de los pacientes.
Palabras clave: Atención farmacéutica, Calidad de vida, Ensayo clínico controlado, Epilepsia, Mujer con epilepsia,
Resultados reportados por los pacientesIntroduction
Epilepsy is a complex neurological disorder that has deep
physical, social, emotional and economic repercussions
for patients and their environment. According to the
World Health Organization, more than 20 million women
worldwide suffer from epilepsy and 85% of them live in
developing countries.
For the treatment of epilepsy, the gender of the patient
should be considered because there are conditions,
including hormonal (menstrual cycle, contraception and
menopause), reproductive (fertility, pregnancy and lacta-
tion) and role (childcare) conditions, that can affect and
be affected by anticonvulsant therapy and that change
during the different stages of life of women. In women
with epilepsy (WWE), major adverse reactions such as
reproductive endocrine disorders, hirsutism, polycystic
ovarian syndrome, obesity and sexual dysfunction have
been reported, making the treatment of women more
complex [1-3].
Several studies have shown that people with epilepsy
have lower health-related quality of life (HRQOL),
especially women [4-6], and have associated it with
depression, adverse effects, a greater number of
anticonvulsants and a higher frequency of seizures
[7-10].Anticonvulsants are considered the cornerstone of the
treatment of epilepsy and are characterised by a narrow
therapeutic index, high inter- and intraindividual vari-
ability, a large number of interactions and side effects
and some of them have zero order kinetics.
It has been established that WWE require support and
specific information in order to achieve adequate control
of their condition. The European Declaration on Epilepsy
recommends interdisciplinary action to help people with
epilepsy understand their condition and make the search
for a proper treatment possible in order to improve their
quality of life [11,12].
Pharmaceutical care (PC) is the practice that optimises
pharmaceutical treatments contributing to an improve-
ment in HRQOL (humanistic outcome of therapeutic
relevance) which can be reported directly by the patient
as a patient-reported outcome (PRO) without requiring
an interpretation of the response by others [13-16].
The pharmacist, as a professional healthcare expert on
drugs, can contribute to the optimisation of treatment
using medication review follow-up (MRF), education in
pathology and lifestyle in the management of epilepsy,
therapeutic drug monitoring (TDM) and information on
interactions, adverse effects and the appropriate use of
medications [17,18].
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lishing the impact of the application of a pharmaceutical
care programme on HRQOL in WWE.Patients and methods
The study was conducted in the Fundación Liga Central
Contra la Epilepsia, sede Bogotá (LICCE), a non-profit
organisation specialising in the treatment of outpatients
with epilepsy and a referral centre for the management of
this disorder in Colombia. Annually about 1000 patients
consult for epilepsy, either referred by their health service
or independently. An MRF service was implemented in
the institution and a guide to medication review follow-up
for patients with epilepsy was elaborated and used as the
basis for the study intervention.
The study’s protocol was approved by the Ethics Com-
mittee of the LICCE on August 11, 2009 (ref: IEC-A1 Act
18 of 2009). All patients signed to give their informed con-
sent before entering the study. The patients were invited
to participate by posting notices at the institution and via
phone calls to the WWE who met the inclusion criteria
according to the review of the medical records of patients
who were attending the LICCE. Patient recruitment began
on June 16, 2010 and was completed on March 10, 2012.
The latest follow-up interview took place on September
27, 2012.Study design
This study is a pragmatic, randomised controlled clinical
trial (RCT) of parallel groups.Inclusion criteria
Women over 18 years of age were included if they had been
diagnosed with epilepsy for over a year, were receiving
out-patient treatment with anticonvulsants and had
experienced at least one seizure in the last three years.
Participants also had to have the ability to complete
questionnaires.Exclusion criteria
WWE with psychiatric or neurological diseases diagnosed
by a specialist that prevented them from making a judge-
ment on their quality of life were excluded. Also excluded
were patients with physical (e.g., hemiplegia) or mental
deficits (e.g., mental retardation), making it impossible for
them to answer the questionnaires, and those with a his-
tory of drug or alcohol abuse. Patients who had attended
the LICCE’s MRF service before were also excluded.Intervention
A pharmaceutical care programme was applied, consist-
ing of five parts:1. Medication review follow-up according to Dáder’s
method for a period of six months. Dáder’s method
sought to discover drug-related problems (DRPs) in
order to prevent and resolve drug-related negative
outcomes (DNOs). This method is divided into seven
stages – service offering, first interview, state of affairs,
study phase, evaluation phase, intervention phase
and subsequent interviews – rendering the process
continuous [19]. In the service offering it was explained
to the patient the kind of health care they would
receive. In the first interview, information on health
problems, use of medications and lifestyle habits were
collected. In the state of affairs we established the
relationship between DRPs and medications and in the
study phase we searched for objective information
about these. In the evaluation phase we identified the
DNOs in order to establish needs and designed an
intervention action plan for each patient. Subsequent
interviews (monthly or bimonthly) were performed
according to the conditions of each patient. If
necessary, they were conducted by telephone.
2. Lectures given one Saturday a month in group
education sessions on the following topics: Epilepsy in
women, Quality of life and epilepsy, Pharmacological
and non-pharmacological treatment in epilepsy,
Contraception, Fertility, Pregnancy and childbirth,
Sleep hygiene, Breastfeeding and homecare,
Menopause and bone health and How to improve
memory. These conferences were designed specifically
for WWE and were given by the principal investigator
in order to resolve questions and doubts. The dates of
lectures were scheduled six months in advance and
patients received a reminder e-mail or a call a few
days before the conference.
During the MRF interviews, education was
reinforced in the different pathologies of each
patient, in the proper use of medications, in different
habits of life and in the management of adverse
effects. A guide for patients with epilepsy [20] was
sent by e-mail so that it could be discussed in
subsequent interviews.
In order to complement the verbal information,
specific brochures were delivered according to the
needs of each patient. These included: What to do
in a seizure, Tips to improve sleep, Constipation
management, Menopause management and bone
health, Stress management, Effects of epilepsy on
learning and memory, Breathing management, List
of calcium-rich foods and Workbook for memory.
At conferences and MRF interviews the importance
of lifestyle was emphasised, including seven hours of
continuous sleep, stress management and low
consumption of alcohol or caffeine and other
stimulants of the central nervous system.
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in controlling epilepsy was explained to patients,
emphasising the importance of always taking them
at the same time. For the patients who took multiple
medications, a medication record was developed and
aids were given to optimise adherence, such as a pill
box (with a demonstration of its use) and an alarm
clock as a reminder of when medications should
be taken.
4. Registration of seizures and possible triggers: at the
end of the first interview a seizure journal (calendar)
with instructions on how to fill it out was given to
patients in order to record the frequency of seizures
and whether there were triggers (menstruation, sleep
problems, stress, infection, fever or use of other
drugs) that could be detected and used for the
management of epilepsy.
5. Therapeutic drug monitoring of anticonvulsants was
provided for patients who met any of the inclusion
criteria in accordance with the guidelines of the
International League Against Epilepsy [21]. They were
given instructions for the proper conditions of the
blood sampling and the cost was assumed by the study.
The PC programme was conducted by a pharmacist
trained in the management of patients with epilepsy and
the application of Dáder’s method [19].
Control group
The patients in the control group (CG) received the usual
care in the institution. The first interview was conducted
according Dáder’s method for establishing baseline condi-
tions, and a seizure journal (calendar) was given with
instructions to fill it out for six months and then bring it
to the second application of the questionnaires. These
patients received the brochure “What to do in a seizure”
with the respective explanation.
Outcomes
The impact was assessed by the changes in seizure
frequency, in the self-administered questionnaires (the
Quality of Life in Epilepsy Inventory-31 (QOLIE-31),
Liverpool Adverse Events Profile (Liverpool AEP), Center
for Epidemiologic Studies Depression Scale (CES-D),
Haynes-Sackett test and Moriski-Green test) and between
the first interview and the one at the end of six months of
follow-up. After each patient had answered the question-
naires, the pharmacist checked them and in case of
missing answers, asked the patient to complete them.
The primary outcome was HRQOL measured by the
QOLIE-31, translated into Spanish and validated in Spain’s
version [22]. This questionnaire allows the quantification
of the patient’s experience (PROs) by assessing seven areas
of quality of life (Energy/Fatigue, Emotional well-being,Social functioning, Cognitive functioning, Medication
effects, Seizure worry and Overall quality of life) with a
Likert scale, allowing patients to obtain a score between
0 and 100 points, where a higher score indicates better
quality of life. A QOLIE-31 overall score was derived by
weighting and summing QOLIE-31 scale scores according
the manual [16,23].
The following secondary outcomes were considered:
1. Frequency of crisis: a clinical variable for evaluating
the effectiveness of treatment, it was classified into
eight categories (see Table 1) and self-registered in a
format by the patient [24].
2. Adverse reactions: determined with the Liverpool
AEP translated and validated in Spanish. This 19-
item questionnaire was designed to determine the
frequency of the adverse effects of anticonvulsants
and has the advantage of being short and easy to
complete [16,25]. It rates between 19 and 76 and is
inversely correlated with quality of life: scores below
45 are associated with low toxicity and those equal
to or greater than 45 with high toxicity [26].
3. Depression: measured using the questionnaire
of the CES-D, translated into Spanish and validated
in Colombia [27]. This is one of the most used
questionnaires to assess depression in a non-
psychiatric population; it scores values between 0
and 60 where a higher score is associated with major
depression [28]. In the validation in Colombia, a
value of 20 was established as the cutoff point, since
this value is considered to indicate that the patient
has clinically significant depressive symptoms.
4. Adherence: at the end of the interview, the
pharmacist administered the Haynes-Sackett test
and the Moriski-Green test to assess patients’
adherence to drug treatment [29,30].
Other variables: in the first interview questions were
included on occupation, marital status, education, family
history of epilepsy, birth control and lifestyle habits,
such as hours of continuous sleep, alcohol and coffee
consumption and cigarette use.
Sample size was calculated using an “independent
means comparison” method for the main outcome of
quality of life. We expected a standard deviation of 12,
mean differences from 50 to 55, a ratio between sam-
ples (B/A) of 1, a confidence level of 95% and a test
power of 80%, whereby a sample size of 91 patients was
obtained in each arm. To calculate the sample size an
SD of 12 was used because in an Iranian study with
epilepsy patients they reported that polymedicated
patients had a QOLIE-31 of 46.98 (SD:12.07) [31], and
in a preliminary study in the LICCE we found that
80.6% of WWE who attended the MRF service were








Average age in years (SD) 34.2 (13.3) 34.7 (12.53) 36.2 (14.29) 0.6507 0.5163
Age range (years) 18 to 75 18 to 75 18 to 67
Marital status - No. (%) 3.6093 0.3069
No partner 123 (67.6) 45 (64.3) 50 (67.6)
Married or commonlaw 59 (32.4) 25 (35.7) 24 (32.4)
Educational level - No. (%) 4.8222 0.438
Lower high school or below 32 (17.6) 10 (14.3) 17 (23.0)
High school 110 (60.4) 43 (61.4) 40 (54.1)
University 40 (22.0) 17 (24.3) 17 (23.0)
Occupation - No. (%) 3.0313 0.6952
Working 78 (42.9) 31 (44.3) 32 (42.3)
Housewife 33 (18.1) 11 (15.7) 15 (20.3)
Student 40 (23.0) 17 (24.3) 13 (17.6)
Retired 2 (1.1) 1 (1.4) 1 (1.4)
Unemployed 29 (15.9) 10 (14.3) 13 (17.6)
Epilepsy’s duration in years (SD) 16.8 (12.7) 17.9 (12.5) 17.2 (13.6) −0.3078 0.7587
Age of onset in years (SD) 17.4 (12.5) 16.8 (11.8) 19.0 (14.2) 0.9602 0.3386
Epilepsy type (%) 0.3602 0.8352
Focal 95 (52.2) 38 (54.3) 39 (52.7)
Generalised 79 (43.4) 29 (41.4) 33 (44.6)
Indefinite 8 (4.4) 3 (4.3) 2 (2.7)
Seizure frequency - No. (%) 5.9622 0.5442
One in the past 3 years 27 (14.8) 13 (18.6) 8 (10.8)
One in the last year 36 (19.8) 17 (24.3) 15 (20.3)
One every 6 months 21 (11.5) 5 (7.1) 11 (14.9)
One every 3 months 25 (13.7) 8 (11.4) 9 (12.2)
One per month 47 (25.8) 19 (27.1) 17 (23.0)
One a week 12 (6.6) 5 (7.1) 7 (9.5)
More than one a week but less than daily 10 (5.5) 2 (2.9) 6 (8.1)
Daily 3 (1.6) 1 (1.4) 1 (1.4)
Number of anticonvulsants - No. (%) 1.6932 0.1932
One 116 (63.7) 48 (68.6) 43 (58.1)
More than one 66 (36.3) 22 (31.4) 31 (41.9)
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ramme was used for calculations.
The random allocation sequence was generated by
ballot papers drawn from an urn without the principal
investigator and the coordinator knowing the results in
advance. The allocation ratio was 1:1 for the two groups.
The Runs test for randomness was applied to verify if the
experimental units were allocated randomly to the two
groups. The result (Z = −0 to 297, p-value =0.7662) shows
that there is no statistical evidence to reject the hypothesisof complete randomness in the order of allocation of the
patients.
The concealment was performed by placing the ballot
papers in individual, opaque, sealed envelopes, numbered
sequentially, which were handled exclusively by the study
coordinator.
Patients were recruited by the pharmaceutical prog-
ramme officer after scrutiny of the inclusion–exclusion
criteria and the acquisition of signed informed consent.
Immediately after the admission of a patient to the study,
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bered sequentially to establish the group that she entered
and register it. The patients did not receive money for
their participation in the study but they were reciprocated
with aids to improve treatment such as brochures, pill
boxes, alarm clocks, top-eyes, top-ears, an elaboration
of “Registering taking medication” and free TDM of
anticonvulsants.
Although the study was not blinded, it was explained
to the patients that due to the large number of patients,
all could not be served at the same time and therefore
the study was conducted in two stages whose sequence
was decided randomly, so they could begin the process
of PC immediately, or do it six months after the second
questionnaire session. In this way the effect of knowing
the group assigned was avoided and those in the CG
were rewarded for their participation in the study
programme by receiving PC after answering the ques-
tionnaires the second time.
The study was blind to the LICCE neurologists. They
were informed that the RCT was taking place in the
institution but did not know which patients were par-
ticipating in the trial. In the MRF service we attended
LICCE patients who were not included in the RCT.
Due to the study’s design, the principal investigator was
not blinded to the patients’ allocation.
Statistical methods: Through the evaluation of the
study results, the null hypothesis of the equality of mean
scores in the QOLIE-31 after application of the PC prog-
ramme was established (μIG = μCG) versus the alternative,
that mean scores are different (μIG ≠ μCG).
A complete case analysis was conducted, omitting the
data from lost patients. It was considered inappropriate to
perform data analysis by imputation because for the
second HRQOL assessment the change (Δ) in each patient
needed to be established.
An analysis for intention to treat was done with the
patients who completed the second application of ques-
tionnaires, although these patients had not attended the
MRF interviews or the health education lectures in the
PC programme.
An exploratory and descriptive data analysis was con-
ducted for the sociodemographic and clinical character-
isation of the patients via the information registered in
interviews and medical records. In addition, it was veri-
fied using a Student’s t-test and a Chi-square test that
there were no significant differences between groups at
baseline. The two-sample Kolmogorov-Smirnov test was
used to compare the cumulative distributions of the initial
scores of the QOLIE-31.
To quantify the effect of the PC programme on HRQOL,
the means of the scores were compared between groups at
the end of the study with an independent samples Student’s
t-test. The change (Δ) in scores (QOLIE-31 after-QOLIE-31 before) in the two groups was evaluated using a
paired Student’s t-test. The assumptions of normality in
the residuals and homogeneity of variances between
groups were checked with the Shapiro-Wilk test and
Bartlett’s test respectively. Data processing was performed
in the R programme (version 3.0.1) [33].
To evaluate the clinical significance of the application
of the PC programme, an increase of 10.7 points in the
QOLIE-31 was established as the minimally important
change (MIC) according to studies by Cramer et al. and
Borghs et al. [34,35]. To estimate the strength of associ-
ation the relative risk (RR) and number needed to treat
(NNT) were calculated. Finally, the calculation of RR for
the best- and the worst-case scenario was performed.
Results
We invited 506 patients to participate, of whom 182
entered the study and 144 (79.1%) completed it, 70 in IG
and 74 in CG. The Reasons for withdrawal were job,
economic and family-related and in no case related to
the outcome (Figure 1).
The most widely used anticonvulsant was valproic acid
in 85 patients (46.7%), while carbamazepine was used in
42 (23%), levetiracetam in 22 (12.1%) and lamotrigine in
20 (11%). Most patients (116) were on monotherapy
(63.7%), which is highly recommended for the manage-
ment of this condition, and only four (2.7%) received
three anticonvulsants.
The average value of the QOLIE-31 for the initial
group of 182 patients was 54.56, and confidence interval
(CI 95%) 53.79; 55,33. The two-sample Kolmogorov-
Smirnov test between scores of the initial groups showed
a p-value =0.1686. The homogeneity variances test of
the initial scores of the groups resulted in F =1.02 and a
p-value of 0.94. The t-test results relating to the difference
of the initial mean scores between groups were t = 0.8499,
and CI 95%: −2.56; 6.44, p-value: 0.397.
The t-test of the final mean scores of the QOLIE-31
between groups was t = −2.166, CI 95%: −10.125; −0.4625,
p-value =0.0319.
The mean of the change (Δ) (after-before) in the
QOLIE-31 scores in the final group of 144 patients was
12.45 points in the IG and 2.61 points for the CG. In the
paired t-tests comparing initial and final scores, the
following results were obtained: for the IG t =8.1878 (CI:
9.41; 15.48, p-value <0.001) and for the CG t =1.8259
(CI: −0.24; 5.45, p-value =0.072).
An analysis was performed for each component of the
QOLIE-31 to establish the effect of the PC programme.
The changes (Δ) (after-before) indicated by the scores for
each of the seven components of the QOLIE-31 are pre-
sented in Figure 2. Categorisation of the QOLIE-31 scores
before and after application of the PC programme was
performed according to quality of life (see Figure 3) [36].
o
Figure 1 Flow diagramme.
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IG patients who attended at least three MRF interviews
(61/70) during the application of the PC programme (ana-
lysis per protocol) was 14.41 (CI: 11.37; 17.45).
The contingency table was made with an increase of
10.7 points in the QOLIE-31 score taken as the minimally
important change [34]. Epidemiological parameters wereFigure 2 Changes (after-before) in the Quality of Life in Epilepsy Invecalculated finding a RR of 2.17 (CI: 1.37; 3.43) and a NNT
of 3.5. The RR was 3.22 for the best-case scenario and
1.06 for the worst-case scenario.
Attendance at health education conferences fluctuated
between 28% and 3%. The seizure journal was returned
six months after, at the end of the study, by 54 (37.5%)
of the 144 patients.ntory-31 (QOLIE-31) scores by components.
Figure 3 Classification of quality of life according to the initial and final QOLIE-31 scores.
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Sackett and Moriski– Green tests will be published in
subsequent papers.Discussion
To our knowledge this is the first RCT investigating the
impact of a programme of PC on HRQOL among patients
with epilepsy.
The number of patients lost to follow-up was similar
in both groups. Table 1 reveals that the characteristics of
the groups, after losses, do not differ from those of the
entire group of patients who entered the study. The initial
QOLIE-31’s mean scores, of the patients who remained in
the study, did not present statistically significant differ-
ences between groups (Table 2).
The t-test for the final scores of the QOLIE-31 estab-
lished a statistically significant difference (p-value =0.0319)
with an increase in the HRQOL after the application of the
PC programme in the IG. The paired t-tests to compare
the initial and final scores showed that there is a statistically
significant difference in the change of the scores of the
QOLIE-31 in the IG (p-value <0,001), but not in the CG
(p-value =0,072) confirming that the intervention does







QOLIE-31 before (CI 95%) 51.9 (50.40; 56.78) 56.5 (52.31; 58.74)
QOLIE-31 after (CI 95%) 64.4 (61:00; 67.78) 59.1 (55.61; 62.58)
Change (Δ) QOLIE-31
after- before
12.45 (9.41; 15.48) 2.61 (−0.24; 5.45)
p-value <0.001 0.072The increase of 12.45 points in the QOLIE-31 scores of
the IG is considered clinically significant according to the
study by Borghs et al. and Cramer et al. of the Epilepsy
Impact Project Group, where they established the minim-
ally important change of 10.7 points for the QOLIE-31 in
patients passing to monotherapy, who are the most similar
to the patients in this study [34,35].
The individual analyses of the seven components of
the QOLIE-31 allowed us to establish that the changes
(Δ) were positive in all cases and they were always
higher for the IG (Figure 2). Seizure worry, social and
cognitive functioning presented significant differences. It
is possible that the improvements in social and cognitive
functions are due to the clarifications made in the MRF
interviews, to the WWE and his family, about the use of
medications, diseases, lifestyle habits (allowed to have up
to 2 beers/celebration, attend evening meetings, adjusting
sleeping schedules to 7 h uninterrupted, the importance
of hobbies and activities for stress management, etc.).
Learning this information from a pharmacist and resolving
their doubts could have led to a reduction in their fear of
social activities and the self-stress of living with this
disease. The increase in HRQOL in the drug component
was small, possibly due to the fact that the follow-up
period of six months is too short for evaluating the
benefits of optimized drug therapy. Additionally, the
QOLIE-31 includes only three questions to evaluate the
effect of drugs and gives them the lowest weight (0.03)
throughout the questionnaire, while a total of eleven
questions are devoted to either social or cognitive function
and they are given the greatest weight in the questionnaire
(0.21 and 0.27 respectively) [23].
Most patients had bad HRQOL at baseline (Figure 3),
which remained in the CG at the end of the study
(p-value =0.1994), but decreased almost to half in the




Increase (Δ) ≥10.7 Increase (Δ) <10.7 Total
Intervention group 37 33 70
Control group 18 56 74
Total 55 89 144
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(p-value <0.001) which makes the positive effect of the
PC programme on HRQOL among WWE evident [37].
Helde et al. conducted a RCT to evaluate the change
in HRQOL with a two-year application of a structured
nurse-led programme among patients with epilepsy [38].
They used the QOLIE-89, which is similar to the QOLIE-
31, and found an initial value of 52.5 ± 1.3 (standardised
error margin) and two years later a change (Δ) of 2.3 ± 7.0
in the IG and 1.5 ± 7.2 for the CG, which is not clinically
significant, according to Wiebe et al., who established an
MIC of 10.1 points for the QOLIE-89 [39].
In the per protocol analysis, an even greater increase
in quality of life for IG patients who attended at least
three interviews of the PC programme during the six
months (Δ) was observed: 14.41 points (CI: 11.37; 17.45).
This result highlights the importance of the continuity of
the process.
The average value of the QOLIE-31 for the initial
group of 182 patients was 54.56 ± 15.36 (SD), similar to
the one found by Almeida Souza Tedrus et al. with a value
of 58.37 ± 17.31 (SD) for WWE in Brazil [4], where the
gap between women and men was statistically significant
at 7.57 points (p-value: 0.012). It was also similar to the
value of 53.4 ± 14.7 (SD) reported by Alanis-Guevara et al.
for WWE in Mexico [5]. In both cases HRQOL was lower
in women [6].
In a prospective study performed by Kanjanasilp et al.,
PC was provided for six months among patients with
epilepsy treated with phenytoin; they measured HRQOL
before and after the intervention with the QOLIE-31 and
found that it increased from 61.15 ± 13.67 to 63.47 ±
16.11, showing a statistically significant increase of 2.32
points [40].
The increase in the QOLIE-31 scores in our CG in the
second application could be due to the fact that during
the first interview, according to Dáder’s method, patients
expressed their doubts regarding treatment and patholo-
gies, and the pharmacist, for ethical reasons, had to answer
the concerns and correct the patients when errors were
found in the administration of medications, although this
could lead to the contamination of the group. In a before-
after study conducted in adults with epilepsy by Fogg et al.
[41], the effect of a single 30-minute consultation with a
pharmacist was evaluated using the QOLIE-10, and they
found that HRQOL increased by 4.2 points (CI 95%: 0.4;
8.0). Although this is a different questionnaire, an increase
in HRQOL due to a single consultation with a pharmacist
was observed, just as it was in our CG.
The clinical significance of the implementation of the
PC programme was evaluated (see Table 3), finding that
the possibility of obtaining an MIC in the IG is 2.17
times the CG’s one, even though that PC was presented
to the CG during the first interview. The result couldhave been higher if this confounding bias had not been
introduced.
By performing the sensitivity analysis, we found that
for both the best- and the worst-case scenario the value
of RR is higher than 1, confirming that the intervention
does serve to improve HRQOL and that the result is due
to the implementation of the PC programme. Sensitivity
analysis also allows us to assess the impact of loss of
follow-up. We found the values were not very different
from each other (RR for the worst scenario: 1.06 and for
the best scenario: 3.22). We deduce from this that the
losses did not affect the validity of the study. Addition-
ally, we believe that the results were not biased because
the losses were not related to HRQOL. The effect of the
intervention is notable because, despite the losses, which
led to a significant reduction in sample size (and in the
power of the study), clinically and statistically significant
differences were found in both the ITT analysis and in
the PP analysis.
The NNT found allows us to recommend the imple-
mentation of the PC programme for the additional benefit
that would be obtained in patients’ HRQOL.
Unfortunately, conference attendance was very low des-
pite being scheduled six months in advance, with the most
common reason for the absence being lack of time.
The seizure journal was delivered by only 54 (37.5%)
of the 144 patients, possibly because they had never used
it and therefore did not realise its importance, despite
the explanation and recommendation about filling it out.
This result could also be due to the fact that it was given
at the end of the first interview, after about an hour of
consultation with the application of five questionnaires,
and patients were tired and may not have understood
the purpose of completing this seizure journal.
We believe that the study by a single researcher, quali-
fied and experienced in the management of patients with
epilepsy and in the implementation of pharmaceutical
care, allowed an homogeneous intervention. The bias of
the researcher was minimised by measuring the out-
comes with a patient-reported outcome questionnaire
that does not require interpretation.
Initially, an inclusion criterion of having had at least
one crisis in the last year (85.2% met this condition) was
established, focussing on patients with greater difficulty
controlling the disease, but given the slow rate of
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ion to at least one seizure in the last three years.
Study’s limitations
Due to the study design, the pharmacist who performed
the procedure was not blinded to the allocation of the
patients.
Of the QOLIE-31 versions available in Spanish, Spain’s
version was selected for being very similar to Colombia’s
Spanish. According to our knowledge, of all the question-
naires used, only the CES-D is validated in Colombia.
Conclusions
The study allowed us to demonstrate that the application of
a pharmaceutical care programme significantly improves
HRQOL in WWE. The NNT we found allows the recom-
mendation to implement the PC programme for the add-
itional benefit that would be obtained in patients’ HRQOL.
Recommendations
Institutions serving WWE should implement pharmaceut-
ical care programs as a public health measure to improve
the HRQOL.
It is recommended to include the pharmacist in the
health team serving the WWE.
It is not convenient to apply five questionnaires in one
sitting because it is very tedious for the patients and it
may induce withdrawal from the study.
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